Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Dose Finding of AD-209 in Essential Hypertension
NCT04218552Phase 2Completed
- Sponsor
- Addpharma, Inc.
- Start
- Feb 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AD-209 in essential hypertension, sponsored by Addpharma, Inc.. Started Feb 2020; status: completed.
02
Drugs
AD-209
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT04218552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04218552.